euro adhoc: Sartorius AG / Financial Figures/Balance Sheet / Group sales revenue currency-adjusted up 0.9% / EBITA of EUR56.8 million achieved / Robust profit in a difficult market environment

--------------------------------------------------------------------------------
Disclosure announcement transmitted by euro adhoc. The issuer is responsible
for the content of this announcement.
--------------------------------------------------------------------------------

Preliminary figures for fiscal 2008

10.02.2009

Sales revenue for the Sartorius Group in fiscal 2008 was EUR611.6
million (2007 pro forma: EUR622.7 mn). This corresponds to a
currency-adjusted increase of 0.9%, or a decrease of 1.8% at the
current exchange rates. Currency-adjusted sales for the Biotechnology
Division were up 0.2% (current exchange rates: -2.6%) to EUR366.0
million (EUR375.9 mn). Revenue for the Mechatronics Division rose
1.8% on a currency-adjusted basis (current exchange rates: 0.5%) to
EUR245.6 million (EUR246.8 mn). Based on constant exchange rates,
order intake edged up 1.6% (Biotechnology Division: +3.0%;
Mechatronics Division: -0.5%).

At EUR56.8 million, earnings before interest, taxes and amortization
(EBITA) were 20.0% below the pro forma underlying figure of EUR71.1
million a year ago. The Biotechnology Division contributed earnings
of EUR39.7 million (EUR49.7 mn) and the Mechatronics Division EUR17.1
million (EUR21.3 mn) to consolidated EBITA. This decline in earnings
essentially resulted from the negative exchange rate impact, the
market-induced decline in sales in North America for the
Biotechnology Division and from the budgeted substantial increase in
R&D expenses for the Mechatronics Division. The consolidated EBITA
margin was 9.3% (11.4%).

The financial result decreased from -EUR11.8 million to -EUR23.7
million, especially due to the expenses for currency exchange rate
hedging instruments of -EUR5.2 million and the non-cash item of
interest expense for share price warrants of -EUR2.7 million. Net
profit after minority interest totaled EUR12.4 million (EUR27.0 mn).
Excluding the two non-cash items of amortization and interest for
share price warrants, this corresponds to earnings per share of
EUR1.07 euros (EUR1.78).

Over the coming months, company management expects highly difficult
market conditions for the Mechatronics Division and, therefore, a
decline in sales for fiscal 2009. For the Biotechnology Division, the
company plans to achieve revenue growth. However, as high uncertainty
continues to prevail over the global economical development,
Sartorius upholds its opinion that for both divisions it is not
possible to make a reliable forecast on development of business in
2009.

The numbers provided above are still subject to final review by the
auditors. The final audited figures will be announced at the annual
press conference on March 12, 2009.

Dr. Joachim Kreuzburg, CEO and Executive Board Chairman of Sartorius,
will discuss the results with analysts and investors on Wednesday,
February 11, 2009, at 3:00 p.m. Central European Time (CET), in a
teleconference. You may dial into the tele-conference starting at
2:45 CET at the following numbers: Germany: +49 (0)69 5007 1317;
France: +33 (0)1 70 99 42 98; UK: +44 (0)20 7806 1967; USA: +1 718
354 1391. The dial-in code is: 2415076; to view the webcast or
presentation, log onto www.sartorius.com

end of announcement euro adhoc
--------------------------------------------------------------------------------

ots Originaltext: Sartorius AG
Im Internet recherchierbar: http://www.presseportal.de

Further inquiry note:

Andreas Wiederhold

Phone +49(0)551.308.1668

andreas.wiederhold@sartorius.com

Branche: Biotechnology
ISIN: DE0007165607
WKN: 716560
Index: CDAX, Prime All Share, Technologie All Share
Börsen: Börse Frankfurt / regulated dealing/prime standard
Börse Berlin / free trade
Börse Hamburg / free trade
Börse Stuttgart / free trade
Börse Düsseldorf / free trade
Börse Hannover / free trade
Börse München / free trade